Linker Information
General Information of This Linker
| Linker ID |
LIN0VXZMV
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
L19 linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C178H317N19O76
|
|||||
| Isosmiles |
CC([C@H](NC(OCCN(CCOC(N[C@H](C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(C)C(COCC2=CN(N=N2)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(O)=O)=C1)=O)=O)C(C)C)=O)C(CCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCN3C(C=CC3=O)=O)=O)=O)=O)C(N[C@@H](CCCNC(N)=O)C(NC4=CC=C(C)C(COCC5=CN(N=N5)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(O)=O)=C4)=O)=O)C
|
|||||
| InChI |
InChI=1S/C178H317N19O76/c1-151(2)169(173(208)186-161(9-7-21-182-175(179)210)171(206)184-157-13-11-153(5)155(143-157)147-270-149-159-145-195(192-190-159)26-32-217-40-46-223-52-58-229-64-70-235-77-81-240-85-89-244-93-97-248-101-105-252-109-113-256-117-121-260-125-129-264-133-137-268-141-139-266-135-131-262-127-123-258-119-115-254-111-107-250-103-99-246-95-91-242-87-83-238-79-74-233-68-62-227-56-50-221-44-38-215-30-19-167(202)203)188-177(212)272-35-24-194(164(199)17-23-181-163(198)18-29-214-37-43-220-49-55-226-61-67-232-73-76-237-72-66-231-60-54-225-48-42-219-34-28-197-165(200)15-16-166(197)201)25-36-273-178(213)189-170(152(3)4)174(209)187-162(10-8-22-183-176(180)211)172(207)185-158-14-12-154(6)156(144-158)148-271-150-160-146-196(193-191-160)27-33-218-41-47-224-53-59-230-65-71-236-78-82-241-86-90-245-94-98-249-102-106-253-110-114-257-118-122-261-126-130-265-134-138-269-142-140-267-136-132-263-128-124-259-120-116-255-112-108-251-104-100-247-96-92-243-88-84-239-80-75-234-69-63-228-57-51-222-45-39-216-31-20-168(204)205/h11-16,143-146,151-152,161-162,169-170H,7-10,17-142,147-150H2,1-6H3,(H,181,198)(H,184,206)(H,185,207)(H,186,208)(H,187,209)(H,188,212)(H,189,213)(H,202,203)(H,204,205)(H3,179,182,210)(H3,180,183,211)/t161-,162-,169-,170-/m0/s1
|
|||||
| InChIKey |
UCZAPVUDDTUPIS-JRMPWWJNSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
3939.551
|
Polar area
|
1061.45
|
||
|
Complexity
|
.
|
xlogp Value
|
1.39444
|
|||
|
Heavy Count
|
273
|
Rot Bonds
|
214
|
|||
|
Hbond acc
|
80
|
Hbond Donor
|
13
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
NY920-P1-L19-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.037 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.06 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.146 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.16 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in Ke97
|
||||
| In Vitro Model | Bladder carcinoma | Ke97 cells | CVCL_3386 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.216 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.407 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 10 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||